Cellular communication in the cancer environment
================================================

Living organisms depend on receiving and processing information for their survival. Information can be received from the environment in the form of physical or chemical stimuli (ie, variation in temperature and availability of nutrients) that give rise to a variety of responses.[@b1-ott-7-1327] The nature of the response elicited depends on both the nature of the signal transmitted and the type of cell that receives that signal. In eukaryotic organisms, a cell can communicate with itself or with other cells. Intercellular communication allows a population of cells to coordinate and execute biological functions and perform specialized tasks, which could not be accomplished otherwise. For example, the process of morphogenesis is controlled by a group of cells that establishes proper connections with each other.[@b1-ott-7-1327],[@b2-ott-7-1327]

The information exchanged between cells may involve direct cell-to-cell contact (ie, juxtacrine interaction and gap junctions) or the release of soluble mediators which can act over a short distance (autocrine and paracrine mechanisms[@b3-ott-7-1327]) or travel long distances, circulating in blood and body fluids to elicit a response in cells located in tissues at distant organs,[@b4-ott-7-1327] in an endocrine fashion. Intercellular communications operate by means of molecular messengers such as proteins, small peptides, lipids, carbohydrates, and nucleic acids. These molecules are released in the extracellular space to bind to receptors on other cells, thus modifying intracellular signaling in the recipient cells. Following the receptor binding on the target cell, the information is translated into an intracellular signal, which produces a specific behavior in individual cells and in tissues. There is growing evidence that intercellular communication through molecular signals is not a random process.[@b5-ott-7-1327],[@b6-ott-7-1327] In fact, the release of such signals is a tightly regulated process that can involve the production and secretion of a variety of supramolecular structures, including nanotube structures and membranous vesicles (MVs).[@b7-ott-7-1327],[@b8-ott-7-1327] Of particular interest, MVs are complex and dynamic membranous compartments known to act as mediators of intercellular communications due to their capacity to transmit a collection of proteins, lipids, or nucleic acids, including DNA, messenger (m)RNA, and microRNAs (miRNAs), to different recipient cells.[@b8-ott-7-1327],[@b9-ott-7-1327] Once they are released, MVs can either target a neighboring cell or reach a cell located at distant organs after entering the blood stream. The exact mechanisms by which target cells take up and integrate material carried by MVs are poorly understood. This transfer of material is a highly specific process that depends on the type and status of the donor and recipient cells and has different functional consequences. This mechanism of cell-to-cell behavioral regulation is particularly important in cancer.[@b2-ott-7-1327] Through a shedding mechanism, tumor cells are capable of constitutively secreting a variety of MVs, which can potentially exert a paracrine influence on the surrounding cells to promote proliferation,[@b10-ott-7-1327],[@b11-ott-7-1327] stromal remodeling,[@b12-ott-7-1327] angiogenesis,[@b13-ott-7-1327],[@b14-ott-7-1327] and immune evasion[@b15-ott-7-1327],[@b16-ott-7-1327] and invasion[@b11-ott-7-1327],[@b17-ott-7-1327],[@b18-ott-7-1327] of tumor cells and also act in an endocrine way, interacting and releasing their cargo at cells located at distant organs, which could have profound effect on metastasis.[@b17-ott-7-1327],[@b19-ott-7-1327],[@b20-ott-7-1327]

Exosomes serve as signal transporters
=====================================

In 1981, Trams et al[@b21-ott-7-1327] observed that cultures from various normal and neoplastic cell lines shed vesicles with 5′-nucleotidase activity, suggesting that vesicles are derived from specific subdomains of the plasma membrane. Later on, shedding of a particular class of MVs from live cells was proposed to be a mechanism by which cells discard inert debris.[@b22-ott-7-1327] Johnstone[@b23-ott-7-1327] and Harding et al[@b22-ott-7-1327] introduced the term exosomes to refer to this class of MVs, which were involved in the removal of spent transferrin receptors from differentiating reticulocytes. The classification of an MV as an exosome is based primarily on size, density, and membrane composition.[@b24-ott-7-1327]

Exosomes are membrane vesicles that have the same topology as the cell and are approximately 30--100 nm in diameter,[@b9-ott-7-1327],[@b25-ott-7-1327],[@b26-ott-7-1327] though larger exosomes have also been reported.[@b27-ott-7-1327],[@b28-ott-7-1327] Exosomes are vesicles of endocytic origin that are released by most cell types when multivesicular bodies (MVBs) fuse with the plasma membrane.[@b29-ott-7-1327],[@b30-ott-7-1327] As mentioned above, the intercellular exchange of protein, DNA, and RNA via exosomes is a potential mechanism of cell-to-cell communication within the tumor microenvironment. Information regarding exosome content is summarized in Exocarta (<http://www.exocarta.org>).[@b25-ott-7-1327] Moreover, profiling studies have revealed that exosomes of different cellular origin contain a unique expression profile of mRNAs and miRNAs, which may also differ from the signatures of their parent cells.[@b31-ott-7-1327]--[@b33-ott-7-1327]

The mechanisms underlying how exosomes interact with the recipient cells have not yet been clarified. Some studies have demonstrated that exosomes can fuse with the plasma membrane of the target cells, which leads to the release of exosome content into the target cell.[@b33-ott-7-1327],[@b34-ott-7-1327] Although exosomes have been best characterized in cells of the immune system,[@b2-ott-7-1327],[@b35-ott-7-1327] there is evidence that these vesicles are secreted by many, if not most, cell types, and it is clear that they can interact with other cells to evoke paracrine or endocrine responses in these recipient cells.

In particular, miRNAs, natural effector molecules of RNA interference,[@b36-ott-7-1327]--[@b38-ott-7-1327] which are already implicated in cancer development, also play an important role as distant modulators via tumor-released (TR) exosome signaling pathways.

Exosomes are naturally engineered for the selective loading of miRNAs
=====================================================================

The biogenesis, release, and uptake of exosomes are tightly regulated processes governed by diverse signaling mechanisms, which can be altered in pathologies such as cancer to create dysfunctional pathways. Generally, exosome biogenesis,[@b9-ott-7-1327],[@b31-ott-7-1327] material cargo sorting,[@b9-ott-7-1327],[@b39-ott-7-1327] and release[@b40-ott-7-1327] involve the endosomal sorting complex required for transport (ESCRT complex), acting together with associated proteins. The ESCRT complex recognizes ubiquitinated membrane proteins and promotes their internalization into the MVB.[@b41-ott-7-1327] The presence of late endosome components like Alix, (tumor susceptibility gene 101) TSG101, and tetraspanins reveals the MVB origin of exosomes.[@b24-ott-7-1327],[@b42-ott-7-1327] During the endosome formation process, material from the cell cytoplasm including RNA, protein, and DNA is sorted into exosomes.[@b29-ott-7-1327],[@b30-ott-7-1327] The mechanism by which miRNAs package into exosomes remains elusive. Remarkably, there is growing evidence that the miRNA maturation process is linked to the formation and maturation of MVBs and exosomes.

Canonically, the biogenesis of miRNAs starts in the cell nucleus where DNA containing miRNAs is transcribed by RNA polymerase II to generate primary miRNAs (pri-miRNAs).[@b43-ott-7-1327] The pri-miRNAs are processed by a microprocessor complex, consisting of the RNase type III endonuclease Drosha and an essential cofactor (DiGeorge syndrome critical region 8)/Pasha (protein containing two double-stranded RNA binding domains), to generate a precursor miRNA (pre-miRNA).[@b44-ott-7-1327],[@b45-ott-7-1327] Pre-miRNA is then exported to the cytoplasm by the exchange factor of the guanine Ran nucleotide (GTP-binding nuclear protein Ran) and the exportine-5 receptor and is then processed by another RNase type III endonuclease known as Dicer, releasing \~22-nucleotide miRNA duplex. One strand of the RNA duplex is selected to be subsequently loaded into the RNA-induced silencing complex (RISC) along with argonaut (AGO2) and GW182.[@b46-ott-7-1327],[@b47-ott-7-1327] In metazoans, miRNAs loaded into the RISC (miRISC) complex base pair with its target mRNA and induce translational repression and mRNA destabilization[@b48-ott-7-1327]--[@b50-ott-7-1327] ([Figure 1](#f1-ott-7-1327){ref-type="fig"}).

In 2009, two research groups demonstrated the association between GW182 and AGO2, both main components of the RISC and MVBs.[@b51-ott-7-1327],[@b52-ott-7-1327] Gibbings et al[@b51-ott-7-1327] reported that predominantly GW182, but not AGO2, was enriched in the exosomes. Meanwhile, Lee et al[@b52-ott-7-1327] showed that blocking the maturation of MVBs enhanced short interfering RNA (siRNA)- and miRNA-mediated silencing. This evidence suggests an important role for MVBs as a mechanism modulating the formation and the abundance of functional miRISC complex, thus, affecting its activity within the cell. Whether the incorporation of miRNAs into exosomes occurs at the pre-miRNA or mature miRNA level is not well understood. Recently, Villarroya-Beltri et al[@b53-ott-7-1327] reported that mature miRNAs contain specific motifs that control their sorting in exosomes. In addition, they successfully revealed the identity of the trans-acting factor governing the loading of miRNAs into exosomes, the heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1), which after being sumoylated, specifically binds exosomal miRNAs through the recognition of these motifs and controls their loading[@b53-ott-7-1327] ([Figure 1](#f1-ott-7-1327){ref-type="fig"}). Of relevance is the fact that some of the mechanism and pathways involved in exosome production, release, and uptake have been better studied in cancer cell models. In this regard, a recent study by Shen et al[@b54-ott-7-1327] showed that epidermal growth factor receptor (EGFR), a known oncogene, impairs the miRNA maturation process under hypoxic conditions. Strikingly, this novel intracellular function of EGFR occurs through its interaction with components of the RISC complex; therefore, internalization of EGFR could be imposing some type of regulation for the preferential incorporation of pre-miRNAs into MVBs.[@b54-ott-7-1327] Nonetheless, the suggestion that pre-miRNAs are readily incorporated into exosomes and later processed to mature miRNAs would require the presence of members of the RISC-loading complex, namely Dicer or TRBP (TAR RNA binding protein), which to our knowledge has not been reported. What is certain is that diverse studies report that pre-miRNAs as well as mature miRNAs are released in exosomes.[@b55-ott-7-1327]--[@b58-ott-7-1327]

Exosome miRNAs are messages involved in intercellular communication
===================================================================

Our understanding of intercellular communication is mainly based on the secretion of soluble factors, such as growth factors and neurotransmitters, cytokines, and chemokines, and their specific recognition by cell-surface receptors. However, evidence indicating that cells also communicate via the direct exchange of DNA[@b59-ott-7-1327]--[@b61-ott-7-1327] and RNA[@b3-ott-7-1327],[@b62-ott-7-1327] has been growing over the past several years. In 1988, Benner proposed that RNA is involved in cell-to-cell communication as a short-distance and fast-acting messenger.[@b63-ott-7-1327] It has recently been reported that exosomes secreted by mast cell lines contain both mRNA and miRNA.[@b3-ott-7-1327] Several studies have demonstrated that miRNAs are present in a cell-free form in human and mouse serum.[@b34-ott-7-1327],[@b64-ott-7-1327]--[@b66-ott-7-1327] These reports reinforced the idea that RNA could function in long-distance communication between cells. In fact, miRNAs have been found in various body fluids, including serum, plasma, saliva, tears, urine, amniotic fluid, colostrum, breast milk, bronchial lavage, cerebrospinal fluid, peritoneal fluid, pleural fluid, and seminal fluid.[@b67-ott-7-1327] Despite increasing efforts, little is known about the mechanisms that explain the origin and stability of circulating miRNAs in those body fluids.[@b4-ott-7-1327],[@b68-ott-7-1327] It is known that miRNAs can be passively released from broken cells and apoptotic bodies[@b68-ott-7-1327],[@b69-ott-7-1327] and actively secreted as RNA-protein complexes.[@b70-ott-7-1327],[@b71-ott-7-1327] However, an advantage of exosomes as RNA delivery vehicles is that, unlike soluble factors, exosomes are protected from the environment by their lipid bilayer and are more likely to reach their target cells.[@b35-ott-7-1327] In fact, exosomal miRNAs are more stable and resistant to degradation during prolonged storage and freeze--thaw cycles than cellular miRNAs.[@b7-ott-7-1327],[@b72-ott-7-1327],[@b73-ott-7-1327] Another advantage is that exosomes can deliver multiple messages simultaneously, which make them an attractive way of exchanging specific subsets of mRNA, miRNA, or proteins between donor and recipient cells, despite the distance between one and the other. There is increasing evidence that miRNAs are selectively packaged into exosomes.[@b66-ott-7-1327],[@b74-ott-7-1327]--[@b76-ott-7-1327] Therefore, exosomal transport of mRNAs and miRNAs from tumor cells to neighboring cells or cells located at distant organs could have a functional role in the process of tumorigenesis ([Figure 2](#f2-ott-7-1327){ref-type="fig"}).[@b62-ott-7-1327],[@b77-ott-7-1327]

MiRNAs in exosomes from cancer cells: the Trojan horse
======================================================

One of the first pieces of evidence implicating miRNA transport by exosomes as a communication process among cancer cells came from Skog et al,[@b33-ott-7-1327] who demonstrated that the messengers encoding for EGFRvIII protein and miR-21 are transported in glioblastoma-derived exosomes and that these molecules could be taken up by normal host cells and transformed into functional signals, stimulating proliferation of cancer cells.[@b33-ott-7-1327] In a different study, Pegtel et al[@b78-ott-7-1327] demonstrated that mature Epstein--Barr virus (EBV)-encoded miRNAs are secreted by EBV-infected B-cells through exosomes, and that these miRNAs accumulate in neighboring noninfected monocyte-derived dendritic cells (MoDCs). Furthermore, these EBV-miRNAs are functional because after internalization by MoDCs, investigators observed a dose-dependent miRNA-mediated repression of known EBV target genes, including *CXCL11/ITAC*, an immunoregulatory gene downregulated in primary EBV-associated lymphomas.[@b78-ott-7-1327] This may represent some of the first evidence consistent with the idea that miRNAs delivered by exosomes can act as regulators of gene expression in distant cells. Ohshima et al[@b74-ott-7-1327] found that the let-7 miRNA family was abundant in both the intracellular vesicles and exosomes from AZ-P7a cells, a metastatic gastric cancer cell line, while non-metastatic AZ-521, the parent cell line of AZ-P7a, showed no such high levels. This suggests that the exosomal mechanism may be used by tumor cells to launch out miRNAs, which predominately have tumor suppressive functions, preventing them from acting in their parent cell and thus maintaining its oncologic potential. However, whether their release is intended to promote or inhibit oncogenesis remains unclear.[@b74-ott-7-1327] In recent years, the idea that exosomes can affect and modulate the gene expression programs of recipient cells by intercellular signaling has come to be accepted, but to which extent miRNAs account for this mechanism is an issue we are just beginning to understand. Kogure et al[@b79-ott-7-1327] showed that there is a unique set of eleven miRNAs expressed exclusively in exosomes derived from Hep3B human hepatocellular carcinoma cells and that this set of miRNAs targets genes predominantly involved in transforming growth factor beta activated kinase-1 (TAK1) signaling. Strikingly, these TR exosomes can modulate the constitutive expression of *TAK1* and modulate downstream signaling associated with TAK1 in recipient Hep3B cells.[@b79-ott-7-1327] The evidence provided by Shen et al[@b54-ott-7-1327] in the sense that EGFR regulates the maturation of miRNAs in a trafficking-associated mechanism is thought-provoking concerning the functional relevance miRNAs secreted by TR exosomes hold in cancer. Exosomes in cancer have multiple functions including promotion of certain local and systemic processes that lead to cell growth and dissemination, or impairment of the immune system response. In fact, there is growing evidence that TR exosomes might act as a vehicle for suppressive signals and have suppressive effects on antitumor immune responses.[@b80-ott-7-1327],[@b81-ott-7-1327] On the other hand, it has been found that macrophages regulate invasiveness of cancer cells through exosome-mediated delivery of oncogenic miRNAs.[@b82-ott-7-1327]

Role of miRNAs transported by exosomes in metastasis
====================================================

The metastatic process involves the manipulation of the cellular microenvironment to optimize conditions for deposition and growth both locally and at a distance.[@b83-ott-7-1327],[@b84-ott-7-1327] The discovery that miRNAs can function as hormones, entering the circulatory system and travelling to distant organs to deliver their message, where they are actively taken up by recipient cells located there, has pointed to the potential of these regulatory molecules as signals involved in preparing the distant site for tumor colonization.[@b2-ott-7-1327],[@b68-ott-7-1327] On the other hand, it is well established that TR exosomes are contributors to both formation of primary tumors and metastases. In this section, we present examples on how miRNAs secreted in TR exosomes participate in preparing and promoting the metastatic process in cancer. In one such example, it was shown that exosomes released by CD105 cancer stem cells from renal carcinomas may modify the tumor microenvironment by triggering angiogenesis and may promote formation of a pre-metastatic niche.[@b13-ott-7-1327] Interestingly, these vesicles were enriched in miRNAs, which may modulate several biological functions relevant in tumor invasion and metastasis.[@b13-ott-7-1327]

To support the role of miRNAs secreted in TR exosomes in modulating the tumor microenvironment, Zhang et al[@b85-ott-7-1327] found that THP-1-derived (the acute monocytic leukemia cell line) exosomes are incorporated into human HMEC-1 (the human mammary epithelial cell line) cells and deliver miR-150. The elevated exogenous miR-150 effectively reduces c-Myb expression enhancing cell migration.[@b85-ott-7-1327] Exosomes released from dendritic cells can fuse with target dendritic cells and release their contents into the target cells, leading to mRNA silencing.[@b86-ott-7-1327] A collection of studies from different groups provides evidence that miRNAs delivered by TR exosomes into recipient cells can regulate target gene expression and recipient cell function, modulating the tumor microenvironment to adapt it for tumor promotion and progression. This role of miRNAs acting on neighboring cells to transmit a message produced by a donor cell and taken up by a recipient cell resembles a paracrine mechanism of intercellular communication.

In 2008, Hunter et al[@b87-ott-7-1327] identified miRNAs in circulating MVs in the plasma and in peripheral blood mononuclear cells. Interestingly, many of the miRNAs characterized in this study were predicted to regulate homeostasis of hematopoietic cells and metabolic functions. More recently, Hood et al[@b83-ott-7-1327] found that melanoma exosomes are capable of directly tuning a remote lymph node into a microenvironment that facilitates melanoma growth and metastasis even in the local absence of tumor cells. This work provides evidence that TR exosomes can act as a messenger mechanism to signal sites to prepare for eventual metastasis. In recent years, multiple studies have demonstrated the presence of TR exosome miRNAs in circulation.[@b33-ott-7-1327],[@b35-ott-7-1327],[@b87-ott-7-1327]

Until recently, it was believed that miRNAs transported by exosomes exerted their signaling function by regulating the expression of their target mRNA transcripts in the recipient cell. Interestingly, Fabbri et al[@b88-ott-7-1327],[@b89-ott-7-1327] recently demonstrated that miR-21 and -29a secreted by tumor cells via exosomes could bind to toll-like receptor 8 (TLR8) (and TLR7) and activate these receptors on immune cells, leading to TLR-mediated NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation and secretion of prometastatic inflammatory cytokines that may ultimately lead to tumor growth and metastasis. This paramount work does not describe the known molecular function of miRNAs secreted in exosomes, but rather identifies a whole new role, in which miRNAs act as key regulators of the tumor microenvironment by acting as paracrine agonists of TLRs.[@b88-ott-7-1327],[@b89-ott-7-1327] Although these studies support the idea that miRNAs can regulate the different pathways by which cells invade and metastasize to a diversity of sites and organs within the body, the picture is far from complete. In fact, the process of miRNA selection to be packaged and secreted in exosomes derived from tumor cells is affected by the malignant transformation itself. Moreover, accumulating data indicate that vesicles from multiple cells interact with or enter different target cells from other tissues, altering their phenotype,[@b90-ott-7-1327] which poses new questions about the specificity and tropism of exosomes in a particular environment.

Potential of exosome-derived miRNAs as biomarkers: the informant passenger
==========================================================================

To date, different authors have discussed the latest developments in the use of circulating miRNAs as prognostic and predictive biomarkers and their utility in personalized medicine. (For a very recent and comprehensive review on this topic, see Schwarzenbach et al.)[@b104-ott-7-1327] Here, we highlight the efforts aimed at the characterization of miRNAs derived from TR exosomes as surrogate biomarkers of cancer. Different groups have detected miRNAs from TR exosomes in patient plasma of different tumors such as lung cancer,[@b7-ott-7-1327],^91^--[@b93-ott-7-1327] glioblastoma multiforme (GBM),[@b33-ott-7-1327],[@b95-ott-7-1327] malignant glioma,[@b33-ott-7-1327] gastric cancer,[@b11-ott-7-1327] breast cancer,[@b56-ott-7-1327],[@b96-ott-7-1327],[@b97-ott-7-1327] prostate cancer,[@b98-ott-7-1327]--[@b100-ott-7-1327] ovarian carcinoma,[@b32-ott-7-1327] and cervical cancer[@b101-ott-7-1327] ([Table 1](#t1-ott-7-1327){ref-type="table"}). It is widely accepted that resistance to therapy and relapse of cancer remains a central problem in cancer treatment, and this process accounts for much cancer mortality. There is increasing evidence that miRNAs are potential biomarkers for diagnosis and prognosis, and also to monitor treatment response.[@b102-ott-7-1327] Due to the fact that exosomes are released in accessible body fluids such as blood and urine, and can be isolated by minimally invasive methods, miRNAs in exosomes represent a promising biomedical tool, useful as biomarkers in the diagnosis and prognosis of malignant tumors.[@b103-ott-7-1327],[@b104-ott-7-1327] In 2008, Mitchell et al[@b66-ott-7-1327] showed that serum levels of miR-141, a miRNA expressed in prostate cancer, can distinguish patients with prostate cancer from healthy subjects. By this means, they established proof of the principle that tumor-derived miRNAs enter the circulation where their measurement in plasma can serve as a means for cancer detection.[@b66-ott-7-1327] A few years later, Bryant et al[@b100-ott-7-1327] demonstrated significant upregulation of miRNAs derived from TR exosomes in metastatic prostate cancer patients compared with non-recurrent cancer patients. Taylor and Gercel-Taylor[@b32-ott-7-1327] demonstrated the association of miRNAs with circulating tumor-derived exosomes and found that although Epithelial cell adhesion molecule (EpCAM)-positive exosomes were detectable in patients with both benign ovarian disease and ovarian cancer, exosomal miRNA from ovarian cancer patients had similar profiles, which were significantly different from profiles observed in benign disease. In breast cancer, it has been shown that the release of miRNAs from cells into blood, milk, and ductal fluids is selective, and that the selection of released miRNAs may correlate with malignancy.[@b56-ott-7-1327] A different study showed that serum exosomes isolated from patients with esophageal squamous cell carcinoma (ESCC) induces the proliferation of ESCC cells in vitro. Moreover, the authors found that exosomal miR-21 expression is upregulated in serum from patients with ESCC, and this alteration was positively correlated with tumor progression and aggressiveness.[@b105-ott-7-1327] In a recent work, it was found that exposure of A549 lung cancer cells to cisplatin could cause cells to release more exosomes than in normal conditions, and that the interaction of these exosomes with other A549 cells could increase the resistance of these cells to cisplatin.[@b92-ott-7-1327] Another study recently conducted demonstrated that miRNAs derived from TR exosomes after irradiation could be used as indicators of resistance to radiotherapy in GBM.[@b95-ott-7-1327] In lung cancer, Aushev et al[@b93-ott-7-1327] compared circulating miRNA profiles in patients with lung squamous cell carcinoma before and after tumor removal, assuming that the levels of all tumor-relevant miRNAs would drop after the surgery. These authors discovered a specific panel of the miRNAs whose levels decreased strikingly in the blood of patients after lung squamous cell carcinoma surgery. Interestingly some of these miRNAs were selectively secreted in exosomes. In light of these and other findings, it is plausible that the miRNAs enriched in different body fluids are derived from exosomes released by tumor cells under a specific set of stimuli. Therefore, the miRNA content in body fluids may represent the result of a highly refined process of cargo selection, uploading, and secretion in exosomes, and provides reliable information about the identity and status of the cell type from which they are derived and perhaps about the recipient cell, in the setting of the cellular heterogeneity that is characteristic of malignancies.

Therapeutic potential of exosome-derived miRNAs in cancer
=========================================================

Because of their small size and ability to cross biological membranes and protect their mRNA, miRNA, and protein cargo from degradation, exosomes are ideal delivery systems that can be manipulated for the transfer of specific molecules such as miRNAs or anti-miRNAs ([Figure 3](#f3-ott-7-1327){ref-type="fig"}). In an attempt to block miR-9, which is overexpressed in GBM cells and impairs the response to temozolomide, Munoz et al[@b106-ott-7-1327] refined a method for the delivery of an anti-miR-9 molecule from mesenchymal stem cells (MSCs) via release of exosome-type microvesicles. They demonstrated that anti-miR-9 was transferred from MSCs to GBM cells. The delivery of anti-miR-9 to the resistant GBM cells reversed the expression of the multidrug transporter and sensitized the GBM cells to temozolomide, as shown by increased cell death and caspase activity, thus illustrating a potential role for MSCs in the functional delivery of synthetic anti-miR-9 to reverse chemoresistance of GBM cells.[@b106-ott-7-1327] To reinforce the evidence that TR exosomes can serve as vehicles for the delivery of synthetic miRNAs or miRNA inhibitors, a proof of concept study tested whether MSC exosomes could be used as a vehicle for delivery of anti-tumor miRNAs. A miR-146b expression plasmid was transfected into MSCs, and exosomes released by the transfected MSCs were harvested. The study found that intra-tumoral injection of exosomes derived from miR-146-expressing MSCs significantly reduced glioma xenograft growth in a rat model of a primary brain tumor.[@b107-ott-7-1327] Various approaches have made use of TR exosomes as immune modulators.[@b108-ott-7-1327],[@b109-ott-7-1327] However, to our knowledge none of these works have specifically demonstrated the participation of the miRNAs contained in the TR exosomes as modulator molecules in the communication process that influences the immune cell response. Nevertheless, it is highly plausible that miRNA cargo from TR exosomes somehow regulates and helps to reprogram the immune response in cancer.[@b110-ott-7-1327]

To realize the potential of exosomes as miRNA-based drugs, it is necessary to develop more efficient and tissue-specific ways for their delivery. In a paramount work, Alvarez-Erviti et al[@b111-ott-7-1327] developed a method to produce exosomes from self-derived dendritic cells. Dendritic cells were engineered to elicit neuron-specific targeting. Interestingly, after purification of the exosomes released, they loaded them with an exogenous siRNA against *BACE1*, a therapeutic target in Alzheimer's disease, in wild-type mice. The delivery of this exosome-mediated siRNA produced a significant reduction in protein levels in a tissue-specific manner, and these authors point out that nonspecific uptake in other tissues was not observed.[@b111-ott-7-1327] More recently, the therapeutic potential of exosome-mediated siRNA delivery was demonstrated in vitro by the strong knockdown of *RAD51*, a prospective therapeutic target for cancer cells.[@b112-ott-7-1327] Targeting the machinery of production and release of TR exosomes constitutes another potential therapeutic application in cancer.[@b113-ott-7-1327]--[@b115-ott-7-1327] Rab27, a member of the Guanosine-5'-triphosphate-activating proteins that regulate exosome secretion,[@b116-ott-7-1327],[@b117-ott-7-1327] is upregulated in breast cancer, and its elevation is correlated with the presence of lymph node metastasis and advanced clinical stage; furthermore, a significant positive relationship has been observed between Rab27b and epithelial mesenchymal transition markers.[@b118-ott-7-1327] Moreover, Rab35 inactivation results in the intracellular accumulation of the vesicles and alters exosome secretion.[@b117-ott-7-1327] In a different example, upregulation of heparanase, an enzyme that cleaves heparan sulfate, enhances exosome secretion in diverse human cancer cell lines.[@b119-ott-7-1327] Mechanical changes can also affect exosome release. For instance, recent data show that loss of adherence in breast cancer cells may induce rapid exosome secretion.[@b120-ott-7-1327] Finally, there are some data about specific exosome uptake mechanisms. One signaling pathway reported in ovarian carcinoma suggests that tumoral exosomes require the expression of phosphatidyl-serine at the exosomal surface to be taken up by natural killer cells.[@b121-ott-7-1327] These reports suggest that by targeting the molecular machinery of exosome production, it is possible to inhibit the pro-oncogenic information carried by TR exosomes, including those messages in the form of miRNAs. A better understanding on the mechanism that regulates the production, secretion, and uptake of exosomes will allow us to tailor exosomes to be selectively delivered to a specific target cell. Indeed, Ohno et al[@b122-ott-7-1327] recently reported that by engineering donor cells to produce modified exosomes with GE11, a peptide that binds to EGFR, expressed in their surfaces could efficiently deliver let-7a miRNA to EGFR-expressing breast cancer cells. Interestingly, the authors showed that GE11-positive exosomes containing let-7 inhibit tumor development in vivo.

Disadvantages of using exosomes in cancer therapy
=================================================

We have pointed out that exosomal miRNAs are capable of affecting a variety of physiological and pathological conditions. Moreover, exploiting the exosome feature as natural carriers of miRNAs[@b112-ott-7-1327] may provide new strategies to develop novel siRNA and miRNA delivery systems as anti-cancer therapy.[@b123-ott-7-1327] Although, TR exosomes have been proven to be tissue and cell specific, therapeutic potential of exosomes in cancer is largely unknown, and further research is necessary,[@b106-ott-7-1327],[@b111-ott-7-1327],[@b122-ott-7-1327] before they can be used clinically. Firstly, TR exosomes incorporate a variety of cellular factors mediating oncogenic and proliferative properties;[@b33-ott-7-1327],[@b92-ott-7-1327],[@b124-ott-7-1327],[@b125-ott-7-1327] more research is required to gain knowledge on the complexity of exosome cargo and the possible interference of unknown secreted factors. Secondly, the biocompatibility between donor and recipient tissues needs to be evaluated; some studies conducted so far highlight the value of using self-derived exosomes to reduce toxicity and ensure immune compatibility.[@b111-ott-7-1327],[@b126-ott-7-1327] As has been discussed, there is evidence that argues in favor of a variety of uptake mechanisms by recipient cells.[@b113-ott-7-1327]--[@b115-ott-7-1327] This evidence leads us to ask about the possibility that exosomes from different origins have an effect onto the same cell type. Furthermore, some physical and molecular stimuli could sensitize cells for the release and uptake of exosomes. In this regard, it has been reported that exososome secretion from normal human mammary epithelial cells and breast cancer cells is stimulated when exposed to a medium containing its own exosomes.[@b127-ott-7-1327] While this study unravel a novel feedback regulatory mechanism for controlling exosome release, the biological and functional consequences of this phenomenon in cancer remains to be answered.

Concluding remarks
==================

This review focuses on the recent literature on miRNA secretion through exosomes and its implications in the process of tumorigenesis. It has been established that exosomes are efficient transporters of multiple signals in intercellular communication, as they allow for delivery of messages regardless of the distance between donor and recipient cells. Several studies have found that exosomes are present in a variety of body fluids and blood. There is growing evidence that these vesicles are particularly enriched in miRNAs. Based on the multiple functions that these miRNA molecules can exert, it seems likely that they may be involved in altering the behavior of recipient cells. Although several studies have shown that cancer cells make use of this mechanism to alter their surrounding microenvironment to promote tumor growth and invasiveness and prepare potential distant sites for metastasis, further research is needed. Firstly, we need to improve our understanding of the mechanisms of sorting, secretion, and uptake of miRNAs contained in exosomes. Secondly, it is important to acquire an understanding of the function of exosome miRNAs in physiological conditions, including but not limited to embryogenesis, organogenesis, and maintaining tissue and organ homeostasis. Finally, the potential of exosomes to deliver miRNAs, and the fact that the latter can act as multifunctional molecules, makes them an attractive approach in the development of therapeutic strategies against tumor cells.
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**Notes:** (**A**) MiRNAs coding genes are transcribed as pri-miRNAs in the nucleus. Next, pri-miRNAs are processed by the microprocessor complex, which is composed by Drosha and DiGeorge syndrome critical region 8 to generate pre-miRNAs. Pre-miRNAs are exported to the cytoplasm by an anti-port transporter called exportin-5. Once in the cytoplasm, the pre-miRNAs are excised by Dicer to generate an intermediary RNA duplex \~22 nucleotides long. One strand of the RNA duplex is selected to be subsequently loaded into the RNA-induced silencing complex (RISC) along with argonaut (AGO2) and GW182 to form mature RISC (miRISC) complex. MiRNAs in the miRISC can base pair with its target mRNA and induce translational repression and mRNA destabilization. If the miRISC does not interact with its target, it can then be selected and sorted into the MVBs, likely through a mechanism involving the protein hnRNPA2B1, which after being sumoylated, specifically binds miRNAs through the recognition of specific sequence motifs in the mature miRNA. Pre-miRNAs loaded into the RISC loading complex (pre-miRISC) may be sorted into MVBs (1). Sorting of pre-miRNAs into exosomes could also be occurring in a sequence-dependent manner (2); this, however, remains uncertain. Exosomes are derived from MVBs, also known as late endosomes. Exosomes containing miRISCs or pre-miRISCs are then secreted into the extracellular space. Black arrows indicate direction of canonic miRNA biogenesis and silencing action. Red arrows indicate direction of processes of miRNA maturation involving MVB production.\
**Abbreviations:** hnRNPA2B1, heterogeneous nuclear ribonucleoprotein A2B1; miRNA, microRNA; miRISC, miRNAs loaded into the RISC; mRNA, messenger RNA; MVB, multivesicular body; pre-miRNA, precursor miRNA; pri-miRNA, primary miRNA; RISC, RNA-induced silencing complex; TRPB, TAR RNA binding protein.](ott-7-1327Fig1){#f1-ott-7-1327}

![Biogenesis, packaging, secretion, and uptake of miRNA transported in exosomes.\
**Notes:** Cancer cells can secrete exosomes, which act in different ways: (1) by acting in a paracrine fashion on recipient neighboring cells, into which miRNAs may carry out their canonical mechanism of post-transcriptional repression or may activate membrane surface receptors (ie, TLRs) to favor tumor growth and invasiveness; and (2) by exerting their function in an endocrine manner by entering the circulation and reaching tissues at distant organs, where they are taken up by recipient cells and condition the formation of a metastatic niche. Green arrows indicate direction of the exosome trafficking. Black arrows indicate direction of canonic miRNA silencing action.\
**Abbreviations:** AGO2, argonaut; RISC, RNA-induced silencing complex; miRNA, microRNA; mRNA, messenger RNA; TLR, toll-like receptor.](ott-7-1327Fig2){#f2-ott-7-1327}

![Molecular approaches for the use of miRNAs derived from TR exosomes as therapeutic tools.\
**Notes:** Exosomes are ideal delivery systems that can be manipulated for the administration of specific molecules such as synthetic miRNAs or anti-miRNAs. (**A**) Synthetic miRNAs may be transfected into an exosome-producing cell (eg, mesenchymal stem cell). Transfected miRNAs are released and delivered to the recipient cell via exosomes. Once they reach the recipient cell, synthetic miRNAs bind and arrest the translation of their canonical target transcripts (1). MiRNAs can also act like ligands to activate membrane surface receptors (2). (**B**) In a similar strategy, anti-miRNA molecules are transfected into exosome-producing cells, where they reduce the levels of endogenous miRNAs in the donor cell, thus diminishing the amount of miRNAs transferred to the recipient cells. (**C**) Alternatively, anti-miRNA molecules can be directly transduced into exosomes and delivered to the recipient cell, where they prevent miRNAs from silencing their cognate mRNA. In a similar fashion, siRNA molecules can be employed to downregulate mRNA targets.\
**Abbreviations:** miRNA, microRNA; mRNA, messenger RNA; MVB, multivesicular body; RISC, RNA-induced silencing complex; siRNA, short interfering RNA; TLR, toll-like receptor; TR, tumor-released; UTR, untranslated region.](ott-7-1327Fig3){#f3-ott-7-1327}

###### 

MiRNAs from tumor-derived exosomes isolated from different body fluids or cell types with potential use as biomarkers

  Tumor type                           Relevant miRNA content                                                                                                                                                            Sample or cell of origin                                                    Study
  ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- -----------------------------------
  Lung adenocarcinoma                  miR-17-3p, miR-21, miR-106a, miR-146, miR-155, miR-191, miR-192, miR-203, miR-205, miR-210, miR-212, miR-214                                                                      Peripheral blood                                                            Rabinowits et al[@b75-ott-7-1327]
  Non-small-cell lung cancer           let-7f and miR-30e-3p                                                                                                                                                             Plasma                                                                      Silva et al^91^
  Lung adenocarcinoma                  miR-21, miR-133b, miR-98, and miR-181a                                                                                                                                            Lung cancer cell line: A549                                                 Xiao et al[@b92-ott-7-1327]
  Lung squamous cell carcinoma         miR-205, miR-19a, miR-19b, miR-30b, and miR-20a                                                                                                                                   Plasma                                                                      Aushev et al[@b93-ott-7-1327]
  Lung adenocarcinoma                  miR-378a, miR-379, miR-139-5p, and miR-200b-5p; miR-151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-100, and miR-154-3p                                                            Plasma                                                                      Cazzoli et al[@b94-ott-7-1327]
  GBM                                  miR-21                                                                                                                                                                            Serum                                                                       Skog et al,[@b33-ott-7-1327]
  GBM                                  miR-1469, miR-320b, miR-320c, miR-191, miR-222, Let-7a, miR-923, miR-1308, miR-3185, miR-351-5p, miR-25, miR-939, miR-30c, miR-422a, miR-221, miR-487a, miR-335\*, and miR-4329   GBM cell lines: LN18 and U87MG                                              Arscott et al,[@b95-ott-7-1327]
  Gastric cancer                       miR-214, miR-221 and miR-222                                                                                                                                                      Cancer tissue-derived mesenchymal stem cells                                Wang et al[@b11-ott-7-1327]
  Breast cancer                        miR-16, miR-1246, miR-451 and miR-720                                                                                                                                             Breast cancer cell line MCF7 cells, breast ductal lavages, milk and blood   Pigati et al[@b56-ott-7-1327]
  Breast cancer                        miR-200a, miR-200c and miR-205                                                                                                                                                    Serum                                                                       Rupp et al[@b97-ott-7-1327]
  Basal-like ductal breast carcinoma   miR-140, miR-29a, and miR-21                                                                                                                                                      Tumor isolated CD49f+/CD24− stem-like cells                                 Li et al[@b97-ott-7-1327]
  Prostate cancer                      miR-141                                                                                                                                                                           Serum                                                                       Mitchell et al[@b66-ott-7-1327]
  Prostate cancer                      miR-4258, miR-711, miR-221, miR-193a-3p, miR-30e, miR-1297, miR-129\* and miR-21\*                                                                                                Prostate cancer cell line: PC3                                              Hessvik et al[@b98-ott-7-1327]
  Prostate cancer                      miR-485-3p                                                                                                                                                                        Prostate cancer cell line: DU-145                                           Lucotti et al[@b99-ott-7-1327]
  Prostate cancer                      miR-107, miR-141, miR-375, and miR-574-3p                                                                                                                                         Blood, urine sediment and tissue                                            Bryant et al[@b100-ott-7-1327]
  Ovarian cancer                       miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205, and miR-214                                                                                                      Serum                                                                       Taylor et al[@b32-ott-7-1327]
  Cervical cancer                      miR-21 and miR-146a                                                                                                                                                               Cervicovaginal lavage                                                       Liu et al[@b101-ott-7-1327]
  Esophageal squamous cell carcinoma   miR-21                                                                                                                                                                            Serum                                                                       Tanaka et al[@b105-ott-7-1327]
  Hepatocellular carcinoma             miR-584, miR-517c, miR-378, miR-520f, miR-142-5p, miR-451, miR-518d, miR-215, miR-376a\*, miR-133b, and miR-367                                                                   Hepatocyte carcinoma cell line                                              Kogure et al[@b79-ott-7-1327]

**Abbreviations:** GBM, glioblastoma multiforme; miRNA, microRNA.
